Maze Therapeutics (MAZE) Competitors $13.49 +0.26 (+1.97%) As of 08/22/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MAZE vs. RXRX, TARS, OCUL, BLTE, IDYA, AGIO, DNLI, IRON, HRMY, and GLPGShould you be buying Maze Therapeutics stock or one of its competitors? The main competitors of Maze Therapeutics include Recursion Pharmaceuticals (RXRX), Tarsus Pharmaceuticals (TARS), Ocular Therapeutix (OCUL), Belite Bio (BLTE), IDEAYA Biosciences (IDYA), Agios Pharmaceuticals (AGIO), Denali Therapeutics (DNLI), Disc Medicine (IRON), Harmony Biosciences (HRMY), and Galapagos (GLPG). These companies are all part of the "pharmaceutical products" industry. Maze Therapeutics vs. Its Competitors Recursion Pharmaceuticals Tarsus Pharmaceuticals Ocular Therapeutix Belite Bio IDEAYA Biosciences Agios Pharmaceuticals Denali Therapeutics Disc Medicine Harmony Biosciences Galapagos Maze Therapeutics (NASDAQ:MAZE) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk. Do insiders & institutionals believe in MAZE or RXRX? 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 8.4% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has stronger valuation & earnings, MAZE or RXRX? Maze Therapeutics has higher revenue and earnings than Recursion Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaze Therapeutics$167.50M3.53$52.23MN/AN/ARecursion Pharmaceuticals$58.84M36.45-$463.66M-$1.78-2.78 Do analysts prefer MAZE or RXRX? Maze Therapeutics currently has a consensus target price of $25.60, indicating a potential upside of 89.77%. Recursion Pharmaceuticals has a consensus target price of $7.00, indicating a potential upside of 41.70%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Maze Therapeutics is more favorable than Recursion Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maze Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Recursion Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is MAZE or RXRX more profitable? Maze Therapeutics has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -1,004.91%. Maze Therapeutics' return on equity of 0.00% beat Recursion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Maze TherapeuticsN/A N/A N/A Recursion Pharmaceuticals -1,004.91%-76.09%-54.29% Does the media favor MAZE or RXRX? In the previous week, Maze Therapeutics and Maze Therapeutics both had 13 articles in the media. Recursion Pharmaceuticals' average media sentiment score of 0.78 beat Maze Therapeutics' score of 0.45 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Recursion Pharmaceuticals 7 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive SummaryMaze Therapeutics beats Recursion Pharmaceuticals on 9 of the 13 factors compared between the two stocks. Get Maze Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MAZE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MAZE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MAZE vs. The Competition Export to ExcelMetricMaze TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$580.15M$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E RatioN/A20.8831.1026.05Price / Sales3.53342.78433.22103.03Price / Cash86.4243.1937.7358.48Price / Book2.268.129.536.61Net Income$52.23M-$54.72M$3.26B$265.56M7 Day Performance-0.07%2.63%2.10%1.97%1 Month Performance-23.53%2.78%2.81%-0.36%1 Year PerformanceN/A11.01%30.56%19.03% Maze Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MAZEMaze TherapeuticsN/A$13.49+2.0%$25.60+89.8%N/A$580.15M$167.50M0.00121Positive NewsRXRXRecursion Pharmaceuticals2.5538 of 5 stars$5.77+2.3%$7.00+21.3%-32.8%$2.29B$58.84M-3.24400Positive NewsInsider TradeTARSTarsus Pharmaceuticals1.9342 of 5 stars$54.21+0.1%$66.67+23.0%+126.2%$2.29B$182.95M-23.2750News CoveragePositive NewsOCULOcular Therapeutix4.1041 of 5 stars$12.62-0.2%$17.20+36.3%+37.6%$2.20B$56.66M-9.86230Positive NewsBLTEBelite Bio2.6339 of 5 stars$66.63-3.4%$96.67+45.1%+32.8%$2.20BN/A-42.9910IDYAIDEAYA Biosciences4.5344 of 5 stars$24.33-0.2%$48.09+97.7%-34.5%$2.14B$7M-6.4280Positive NewsAGIOAgios Pharmaceuticals4.3779 of 5 stars$37.01+0.9%$56.33+52.2%-15.1%$2.13B$36.50M3.36390Positive NewsDNLIDenali Therapeutics4.2019 of 5 stars$14.70+1.7%$33.85+130.2%-35.2%$2.11BN/A-5.25430News CoverageIRONDisc Medicine3.5152 of 5 stars$59.86-1.4%$95.73+59.9%+23.8%$2.10BN/A-13.3930HRMYHarmony Biosciences4.6019 of 5 stars$36.87+1.0%$51.00+38.3%+5.1%$2.10B$714.73M11.89200Positive NewsGLPGGalapagos0.1353 of 5 stars$32.47+2.1%$25.33-22.0%+28.6%$2.09B$275.61M0.001,310Positive News Related Companies and Tools Related Companies Recursion Pharmaceuticals Competitors Tarsus Pharmaceuticals Competitors Ocular Therapeutix Competitors Belite Bio Competitors IDEAYA Biosciences Competitors Agios Pharmaceuticals Competitors Denali Therapeutics Competitors Disc Medicine Competitors Harmony Biosciences Competitors Galapagos Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MAZE) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maze Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maze Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access